Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.

Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.

Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 6.8 days from acceptance to publication (median values for papers published in this journal in 2020, 1-2 days of FREE language polishing time is also included in this period).

Free Publication in 2021
Current Issue: 2021  Archive: 2020 2019 2018 2017
Open Access Case Report

Partial Response of Alopecia Areata to Helicobacter Pylori Eradication and Treatment with Low-Dose Naltrexone

Laura Alonso Canal 1, María José Quiles Blanco 2, †, David Jiménez Leiva 3, †, (†), María José González Iglesias 2, †

1. MIP Salud, Calle Conde de Aranda 15, 28001 Madrid, Spain

2. Pediatric Service, San Rafael Hospital, Calle Serrano 199, 28016 Madrid, Spain

3. ATAM, Asociación Telefónica Asistencia Minusválidos, Calle de la Orotava 4, 28660 Boadilla del Monte, Madrid, Spain

† These authors contributed equally to this work.

(†) Passed away before the work was completed.

Correspondence: Laura Alonso Canal

Academic Editor: Tatsuo Kanda

Received: June 26, 2019 | Accepted: September 23, 2019 | Published: September 30, 2019

OBM Hepatology and Gastroenterology 2019, Volume 3, Issue 3, doi:10.21926/obm.hg.1903037

Recommended citation: Alonso Canal L, Quiles Blanco MJ, Jiménez Leiva D, González Iglesias MJ. Partial Response of Alopecia Areata to Helicobacter Pylori Eradication and Treatment with Low-Dose Naltrexone. OBM Hepatology and Gastroenterology 2019;3(3):6; doi:10.21926/obm.hg.1903037.

© 2019 by the authors. This is an open access article distributed under the conditions of the Creative Commons by Attribution License, which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is correctly cited.


Alopecia areata is an autoimmune disease of unknown origin. It has been proposed that it is a multifactorial disease with genetic, immunological, infectious, circulatory, and psychogenic factors being involved in its etiopathogenesis. Its association with other autoimmune diseases is frequent. The infection of Helicobacter pylori has been linked to multiple immuno-mediated extradigestive conditions including alopecia areata. There is scientific evidence of the usefulness of naltrexone in low doses (an opioid antagonist) in autoimmune diseases such as inflammatory bowel disease. We present the case of a patient with alopecia areata who partially responded to the eradication of H. pylori and initiation of treatment with naltrexone.


Helicobacter pylori; alopecia areata; naltrexone; autoimmunity; molecular mimicry

1. Introduction

Alopecia areata is an autoimmune disease associated with hair loss and other autoimmune conditions. The etiology of this condition is unknown but it has been speculated to be caused by genetic, immunological, infectious, circulatory and psychogenic factors [1]. Helicobacter pylori infection has been associated with extra-digestive immune-mediated conditions such as Immune thrombocytopenic purpura (ITP), autoimmune thyroiditis, and psoriasis [2]. Likewise, H. pylori has also been linked to alopecia areata [1,2], where healing after the eradication of infection was observed [2].

There is scientific evidence of the usefulness of naltrexone in low doses (an opioid antagonist) in autoimmune diseases such as inflammatory bowel disease [3] or chronic genetic skin diseases such as familial benign pemphigus (Hailey-Hailey disease) [4]. Earlier studies have also shown some effectiveness in the treatment of rheumatoid and seropositive arthritis (showing a reduction in medication use in patients taking low-dose naltrexone) [5].

Unlike the FDA-approved dose of naltrexone of 50 mg/day that antagonizes opioid receptors, low dose of naltrexone (less than 10 mg/day, usually 0.1 mg/kg/day) has been shown to have anti-inflammatory properties possibly through its action on Toll-like receptors (by selective blockade of opioid receptors on inflammatory cells peripherally through antagonism on Toll-like receptor 4) [6,7] and also by inducing an elevation of endogenous opioids such as endorphins and enkephalins [3]. Naltrexone interacts with the opioid growth factor receptor (OGFr) on immune cells directly as an antagonist or modulates the amount of OGFr agonists like met-enkephalin, thus helping in the minimization of the exaggerated autoimmune response [5]. As it is a nonselective opioid receptor antagonist, it also interacts with other opioid receptors such as mu, kappa, and delta. Safety of this drug in pediatric patients has been established [3].

2. Case

Informed consent was obtained from the parents of the patient prior to the publication of this manuscript.

Here we present the case of a patient with alopecia areata partially ameliorated after the eradication of H. pylori and the initiation of naltrexone treatment.  The patient was an 8-year-old girl who had a sudden onset of alopecia areata at the age of 5 with no known trigger. It was characterized as total alopecia affecting the entire scalp, eyebrows, and eyelashes.

The patient had a history of first-degree relatives with diabetes mellitus type 1 (father), autoimmune hypothyroidism (mother), and celiac disease (sister). The treatment with topical corticosteroids did not yield any positive effect. In addition, the treatment with locally injected corticosteroids was suggested but was dismissed by the parents.

A biopsy of duodenal mucosa without alterations carried out at a different center was available. The genetic susceptibility haplotype of celiac disease was positive (DQ2.5) in the patient. A gluten-free diet was prescribed given the family and genetic history, as well as the existence of documented cases of alopecia areata in celiac patients with a response to a gluten-free diet [8]. However, the symptoms did not improve after following the diet for seven months.

A second digestive endoscopy was performed, which showed antral gastritis without other findings, resulting in a gastric biopsy compatible with chronic H. pylori-positive gastritis and a normal duodenal biopsy. The patient was asymptomatic for gastrointestinal symptoms including, nausea, vomiting, change in appetite or bowel habits.

H. pylori was eradicated with amoxicillin, metronidazole, and omeprazole treatment for ten days following the usual protocol. Likewise, the treatment was started with naltrexone at a dose of 0.1 mg/kg/day, administered orally, which was maintained indefinitely. Moreover, the post-treatment breath test was negative.

The patient began to show hair follicles in bilateral parietal regions two months after the eradication regimen and the initiation of naltrexone treatment. The response was very gradual, with subsequent hair follicles appearing on the eyebrows and eyelashes (Figure 1). Two and a half years after the start of the response, the patient showed considerable improvement, but still there were some alopecia plaques in the temporary regions, in which incipient hair follicles were observed (Figure 2).

The quantification of the degree of alopecia areata in our patient was performed via the manual Salt II score. We considered the affected area as 100% before the treatment, determined it to be 62% after one year of treatment, and 34% after two and a half years. However, even at this point, the outcome was still cosmetically unacceptable [9].

Figure 1 Evolution after one year of treatment.

Figure 2 Evolution after two and a half years of treatment.

3. Discussion

There is no scientific evidence regarding the use of naltrexone in the treatment of alopecia areata. The mechanism of action of naltrexone prompted us to postulate that it could be equally beneficial in our patient since it has been shown to be helpful in other autoimmune diseases [3,5].

In our case, the possible benefit of the patient to scientific interest was prioritized, so both measures (H. pylori eradication and naltrexone initiation) were carried out together. Therefore, it cannot be said whether the positive outcome was due to only one of these procedures or to a combination of both.  Further, cases of spontaneous healing of alopecia areata have been described. However, in our case, such possibility is very improbable due to the temporal coincidence of the start of the aforementioned therapeutic measures with the clinical improvement, as well as the chronicity of the condition in our patient.

The fact that both the eradicating protocol of H. pylori and the treatment with naltrexone in low doses are innocuous to most patients suggests that they could be considered in cases of alopecia areata. The authors suggest the relevance of non-invasive screening for H. pylori infection in these patients. Infection as a trigger is frequent in multiple autoimmune diseases such as rheumatoid arthritis (related to infection by Proteus mirabilis), ankylosing spondylitis (infection by Klebsiella pneumoniae) or Guillain Barré syndrome (infection by Campylobacter jejuni, among others) [10].

 We would like to recommend to our colleagues that while dealing with autoimmune, allergic, and oncological diseases, they should not overlook the possible role of infectious agents as an initiating or perpetuating factor.

Author Contributions

Laura Alonso Canal: main author of the research paper. Rest of authors contributed equally to this work.


No funding was provided.

Competing Interests

The authors have declared that no competing interests exist.


  1. Conde Barreiro S, González Pelegrín B, Clemente Roldán E, Rodrigo Val MP, Yuste Ara A. Possible relation between alopecia areata and enterovirus infections. (Posible relación entre alopecia areata e infecciones por enterovirus). Rev Pediatr Aten Primaria. 2014; 16: 212.e87-e93. [CrossRef]
  2. Campuzano-Maya G. Cure of alopecia areata after eradication of Helicobacter pylori: A new association? World J Gastroenterol. 2011; 17: 3165-3170.
  3. Smith JP, Field D, Bingaman S, Evans R, Mauger D. Safety and tolerability of low dose naltrexone therapy in children with moderate to severe crohn´s disease: A pilot study. J Clin Gastroenterol. 2013; 47: 339-345 [CrossRef]
  4. Ibrahim O, Hogan SR, Vij A, Fernandez AP. Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease). JAMA Dermatol. 2017; 153: 1015-1017. [CrossRef]
  5. Raknes G, Småbrekke L. Low dose naltrexone: Effects on medication in rheumatoid and seropositive arthritis. A nationwide register-based controlled quasi-experimental before-after study. PLoS One. 2019; 14: e0212460. [CrossRef]
  6. Grace PM, Shimizu K, Strand KA, et al. (+)-Naltrexone is neuroprotective and promotes alternative activation in the mouse hippocampus after cardiac arrest/cardiopulmonary resuscitation. Brain Behav Immun. 2015; 48: 115-122. [CrossRef]
  7. Hutchinson MR, Zhang Y, Brown K, et al. Non-stereoselective reversal of neuropathic pain by naloxone and naltrexone: involvement of toll-like receptor 4 (TLR4). Eur J Neurosci. 2008; 28: 20-29. [CrossRef]
  8. Fessatou S, Kostaki M, Karpathios T. Coeliac disease and alopecia areata in childhood. J Paediatr Child Health. 2003; 39: 152-154. [CrossRef]
  9. Olsen EA, Canfield D. SALT II: A new take on the Severity of Alopecia Tool (SALT) for determining percentage scalp hair loss. J Am Acad Dermatol. 2016; 75: 1268-1270. [CrossRef]
  10. Rashid T, Ebringer A. Autoimmunity in rheumatic diseases is induced by microbial infections via crossreactivity or molecular mimicry. Autoimmune Dis. 2012; 2012: 539282. [CrossRef]
Download PDF
0 0